- Home
- EKSO vs PPBT Comparison
EKSO vs PPBT Comparison
Compare EKSO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- PPBT
- Stock Information
- Founded
- EKSO 2005
- PPBT 2010
- Country
- EKSO United States
- PPBT Israel
- Employees
- EKSO 66
- PPBT N/A
- Industry
- EKSO Medical/Dental Instruments
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- PPBT Health Care
- Exchange
- EKSO Nasdaq
- PPBT Nasdaq
- Market Cap
- EKSO 7.7M
- PPBT 6.2M
- IPO Year
- EKSO N/A
- PPBT N/A
- Fundamental
- Price
- EKSO $3.37
- PPBT $2.40
- Analyst Decision
- EKSO Strong Buy
- PPBT Strong Buy
- Analyst Count
- EKSO 2
- PPBT 1
- Target Price
- EKSO $37.50
- PPBT $33.00
- AVG Volume (30 Days)
- EKSO 264.7K
- PPBT 20.0K
- Earning Date
- EKSO 07-28-2025
- PPBT 08-15-2025
- Dividend Yield
- EKSO N/A
- PPBT N/A
- EPS Growth
- EKSO N/A
- PPBT N/A
- EPS
- EKSO N/A
- PPBT N/A
- Revenue
- EKSO $17,544,000.00
- PPBT N/A
- Revenue This Year
- EKSO $0.20
- PPBT N/A
- Revenue Next Year
- EKSO $42.29
- PPBT N/A
- P/E Ratio
- EKSO N/A
- PPBT N/A
- Revenue Growth
- EKSO N/A
- PPBT N/A
- 52 Week Low
- EKSO $2.73
- PPBT $2.00
- 52 Week High
- EKSO $22.95
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- EKSO 41.00
- PPBT 47.27
- Support Level
- EKSO $3.14
- PPBT $2.35
- Resistance Level
- EKSO $3.69
- PPBT $2.58
- Average True Range (ATR)
- EKSO 0.31
- PPBT 0.12
- MACD
- EKSO 0.09
- PPBT 0.01
- Stochastic Oscillator
- EKSO 59.81
- PPBT 43.75
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.